Olema Oncology to Present Two Preclinical Posters on Palazestrant and OP-3136
Olema Oncology will present two preclinical posters at the AACR Annual Meeting on April 20, 2026, detailing palazestrant’s NCoR1 recruitment mechanism (Abstract 2950) and its synergistic anti‐proliferative effects with KAT6 inhibitor OP-3136 (Abstract 2949) in vitro. Each session runs from 2:00–5:00pm PT in the Experimental and Molecular Therapeutics track.
1. AACR Presentation Schedule
Olema Oncology will showcase two preclinical posters on April 20, 2026, at the AACR Annual Meeting in San Diego. Both presentations run from 2:00–5:00pm PT in the Experimental and Molecular Therapeutics: Cellular Responses to Anticancer Drugs session.
2. NCoR1 Recruitment by Palazestrant
Poster 2950 demonstrates that palazestrant directly recruits the NCoR1 corepressor in vitro, leading to complete antagonism of estrogen receptor alpha, underscoring its dual CERAN and SERD activity against ER+ breast cancer.
3. Synergy of Palazestrant and OP-3136
Poster 2949 illustrates that combining palazestrant with OP-3136, a selective KAT6 inhibitor, synergistically downregulates cell proliferation and metastasis‐related gene signatures in breast cancer models, suggesting potential combination benefits.
4. Pipeline Context and Next Steps
Palazestrant is advancing in two Phase 3 trials for ER+/HER2− breast cancer while OP-3136 is enrolling patients in a Phase 1 study. These presentations aim to bolster the compounds’ mechanistic rationale ahead of key clinical readouts.